Education
About Us
Working with TipRanks
Follow Us
Voyager Therapeutics (VYGR)
NASDAQ:VYGR
VYGR Stock Chart & Stats
$4.21
-$0.14(-2.36%)
At close: 4:00 PM EST
$4.21
-$0.14(-2.36%)
Day’s Range― - ―
52-Week Range$2.65 - $6.27
Previous CloseN/A
Volume91.62K
Average Volume (3M)452.56K
Market Cap
$222.40M
Enterprise Value$104.05M
Total Cash (Recent Filing)$208.93M
Total Debt (Recent Filing)$38.37M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Mar 10, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding55,600,082
10 Day Avg. Volume418,771
30 Day Avg. Volume452,559
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.09
Price to Sales (P/S)4.09
P/FCF Ratio-17.36
Enterprise Value/Market Cap0.47
Enterprise Value/Revenue3.32
Enterprise Value/Gross Profit3.32
Enterprise Value/Ebitda-0.78
Forecast
1Y Price Target
$14.00Price Target Upside232.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.1
Revenue Forecast (FY)$34.21M
Bulls Say, Bears Say
Bulls Say
Financial StabilityVoyager Therapeutics reported significant cash reserves of $229 million, providing a financial runway projected to last until 2028.
Innovative PlatformsVoyager's NeuroShuttle platform, which facilitates drug delivery into the brain, is considered innovative and has attracted significant interest in the field.
Strategic CollaborationsVoyager announced a strategic collaboration with Transition Bio, a drug discovery company focused on biomolecular condensates, marking an expansion into small-molecule therapeutics for TDP-43–associated neurodegenerative diseases.
Bears Say
Program TerminationThe termination of JNJ's tau antibody program due to the study failing to achieve statistical significance has cooled expectations for this asset class.
Skepticism In Alzheimer's TreatmentThere is a high level of skepticism among key opinion leaders about the effectiveness of tau antibodies for Alzheimer's Disease.
Strategic ShiftVoyager deprioritized the SOD1-ALS and anti-AB GTx programs to refocus efforts on new discoveries, suggesting a shift in strategic priorities.
Voyager Therapeutics News
VYGR FAQ
What was Voyager Therapeutics’s price range in the past 12 months?
Voyager Therapeutics lowest stock price was $2.65 and its highest was $6.27 in the past 12 months.
What is Voyager Therapeutics’s market cap?
Voyager Therapeutics’s market cap is $222.40M.
When is Voyager Therapeutics’s upcoming earnings report date?
Voyager Therapeutics’s upcoming earnings report date is Mar 10, 2026 which is in 77 days.
How were Voyager Therapeutics’s earnings last quarter?
Voyager Therapeutics released its earnings results on Nov 10, 2025. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.521 by $0.051.
Is Voyager Therapeutics overvalued?
According to Wall Street analysts Voyager Therapeutics’s price is currently Undervalued.
Does Voyager Therapeutics pay dividends?
Voyager Therapeutics does not currently pay dividends.
What is Voyager Therapeutics’s EPS estimate?
Voyager Therapeutics’s EPS estimate is -0.51.
How many shares outstanding does Voyager Therapeutics have?
Voyager Therapeutics has 55,600,082 shares outstanding.
What happened to Voyager Therapeutics’s price movement after its last earnings report?
Voyager Therapeutics reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.521. Following the earnings report the stock price went up 0.709%.
Which hedge fund is a major shareholder of Voyager Therapeutics?
Currently, no hedge funds are holding shares in VYGR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Voyager Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.00 (232.54% Upside)
$14.00 (232.54% Upside)
Blogger Sentiment
Bullish
VYGR Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 706.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $36.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 7.3%
Last 30 Days ▼ 9.5%
Last 30 Days ▼ 9.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.70%
12-Months-Change
Fundamentals
Return on Equity
-46.09%
Trailing 12-Months
Asset Growth
-32.33%
Trailing 12-Months
Company Description
Voyager Therapeutics
Voyager Therapeutics (VYGR) is a biotechnology company focused on developing innovative gene therapies for serious neurological diseases. The company specializes in leveraging its proprietary adeno-associated viral (AAV) vector platform to deliver therapeutic genes directly to the central nervous system. Voyager's core areas of focus include conditions such as Parkinson's disease, Huntington's disease, and other neurodegenerative disorders, with a pipeline that includes both preclinical and clinical-stage programs aimed at addressing significant unmet medical needs.
VYGR Stock 12 Month Forecast
Average Price Target
$14.00
▲(232.54% Upside)
Technical Analysis
Galectin Therapeutics
―
Cartesian Therapeutics
―
Silence Therapeutics
―
Tenaya Therapeutics
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
2.23% Insiders
11.71% Mutual Funds
12.93% Other Institutional Investors
63.42% Public Companies and Individual Investors